Does endothelial cell activation occur with intrauterine growth restriction?

Johnson, Mark R.; Anim-Nyame, Nick; Johnson, P.; Sooranna, S.R.; Steer, Philip

doi:10.1111/j.1471-0528.2002.01045.x

Cited by 70 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the pathogenesis of PIH is poorly understood, the role of the placenta in mediating PIH is well accepted, as the condition is resolved upon delivery of the placenta following childbirth. While the association between angiogenic factors and PIH has been recently discovered (9)(10)(11), numerous reports highlight the proposed contribution of leukocyte activation and several proinflammatory cytokines to the development of PIH, including TNFα (TNF), IL-6, IL-1 receptor antagonist, and IL-8 (12)(13)(14)(15)(16)(17)(18). Further studies implicate a generalized phenomenon of maternal immune cell activation via NFκB, a critical regulator of inflammation (19,20).…”

Section: Introductionmentioning

confidence: 99%

Nicotine Inhibits Cytokine Production by Placenta Cells via NFκB: Potential Role in Pregnancy-Induced Hypertension

Dowling

Rochelson

Way

et al. 2007

Mol Med

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Nicotine Inhibits Cytokine Production by Placenta Cells via NFκB: Potential Role in Pregnancy-Induced Hypertension

Dowling

Rochelson

Way

et al. 2007

Mol Med

View full text Add to dashboard Cite

“…Preeclampsia (PE) and small for gestational age (SGA) neonates share several mechanisms of disease, such as chronic uteroplacental ischemia [1][2][3][4][5][6][7][8] and endothelial cell dysfunction [9][10][11][12][13][14][15]. However, it is unclear why pregnant women with similar insults develop PE, while others deliver an SGA neonate but do not develop PE.…”

Section: Introductionmentioning

confidence: 99%

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

Romero

Nien²,

Espinoza

et al. 2008

The Journal of Maternal-Fetal & Neonatal Medicine

628

498

View full text Add to dashboard Cite

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate, The Journal of Maternal-Fetal & Neonatal Medicine, 21:1, 9-23, DOI: 10.1080/14767050701830480 To link to this article: https://doi.org/10.1080/14767050701830480 Abstract Introduction. Accumulating evidence suggests that an imbalance between pro-angiogenic (i.e., vascular endothelial growth factor (VEGF) and placental growth factor (PlGF)) and anti-angiogenic factors (i.e., soluble VEGF receptor-1 (sVEGFR-1, also referred to as sFlt1)) is involved in the pathophysiology of preeclampsia (PE). Endoglin is a protein that regulates the pro-angiogenic effects of transforming growth factor b, and its soluble form has recently been implicated in the pathophysiology of PE. The objective of this study was to determine if changes in maternal plasma concentration of these angiogenic and anti-angiogenic factors differ prior to development of disease among patients with normal pregnancies and those destined to develop PE (preterm and term) or to deliver a small for gestational age (SGA) neonate. Methods. This longitudinal nested case-control study included 144 singleton pregnancies in the following groups: (1) patients with uncomplicated pregnancies who delivered appropriate for gestational age (AGA) neonates (n ¼ 46); (2) patients who delivered an SGA neonate but did not develop PE (n ¼ 56); and (3) patients who developed PE (n ¼ 42). Longitudinal samples were collected at each prenatal visit, scheduled at 4-week intervals from the first or early second trimester until delivery. Plasma concentrations of soluble endoglin (s-Eng), sVEGFR-1, and PlGF were determined by specific and sensitive ELISA. Results. (1) Patients destined to deliver an SGA neonate had higher plasma concentrations of s-Eng throughout gestation than those with normal pregnancies; (2) patients destined to develop preterm PE and term PE had significantly higher concentrations of s-Eng than those with normal pregnancies at 23 and 30 weeks, respectively (for preterm PE: p 5 0.036 and for term PE: p ¼ 0.002); (3) patients destined to develop PE (term or preterm) and those who delivered an SGA neonate had lower plasma concentrations of PlGF than those with a normal pregnancy throughout gestation, and the maternal plasma concentration of this analyte became detectable later among patients with pregnancy complications, compared to normal pregnant women; (4) there were no significant differences in the plasma concentrations of sVEGFR-1 between patients destined to deliver an SGA neonate and those with normal pregnancies; (5) patients destined to develop preterm and term PE had a significantly higher plasma concentration of sVEGFR-1 at 26 and 29 weeks of gestation than controls (p ¼ 0.009 and p ¼ 0.0199, respectively); and (6) there was no significant difference in the increment of sVEGF...

show abstract

“…SGA is considered a syndrome because smallness at birth can be caused by many factors, including defective placentation [8,51], infection [52,53], chromosomal anomalies [54,55], genetic disorders [56][57][58], and environmental factors [59] such as smoking [60,61], alcohol exposure [62], and cocaine use [63]. Moreover, in a subset of patients without preeclampsia with SGA fetuses, there is also evidence of leukocyte activation [64] as well as endothelial cell dysfunction [65][66][67].…”

Section: Introductionmentioning

confidence: 99%

Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age

Chaiworapongsa

Romero

Gotsch

et al. 2008

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

Objectives. Preeclampsia is considered an anti-angiogenic state. A role for the anti-angiogenic factors soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and soluble endoglin in preeclampsia has been proposed. Soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) has been detected in human plasma, and the recombinant form of this protein has anti-angiogenic activity. There is a paucity of information about maternal plasma sVEGFR-2 concentrations in patients with preeclampsia and those without preeclampsia with small for gestational age (SGA) fetuses. This study was conducted to determine whether: (1) plasma sVEGFR-2 concentration changes throughout pregnancy; and (2) preeclampsia and SGA are associated with abnormalities in the maternal plasma concentration of sVEGFR-2. Study design. This cross-sectional study included non-pregnant women (n ¼ 40), women with normal pregnancies (n ¼ 135), women with an SGA fetus (n ¼ 53), and women with preeclampsia (n ¼ 112). SGA was defined as an ultrasoundestimated fetal weight below the 10 th percentile for gestational age that was confirmed by neonatal birth weight. Plasma concentrations of sVEGFR-2 were determined by ELISA. Results. (1) There was no significant difference in the mean plasma concentration of sVEGFR-2 between non-pregnant women and those with normal pregnancies ( p ¼ 0.8); (2) patients with preeclampsia and those without preeclampsia with SGA fetuses had a lower mean plasma concentration of sVEGFR-2 than that of women with normal pregnancies ( p 5 0.001 for both); and (3) there was no significant difference in the mean plasma concentration of sVEGFR-2 between patients with preeclampsia and those without preeclampsia with SGA ( p ¼ 0.9). Conclusions. Preeclampsia and SGA are associated with low plasma concentrations of sVEGFR-2. One interpretation of the findings is that plasma sVEGFR-2 concentration could reflect endothelial cell function.

show abstract

Does endothelial cell activation occur with intrauterine growth restriction?

Cited by 70 publications

References 27 publications

Nicotine Inhibits Cytokine Production by Placenta Cells via NFκB: Potential Role in Pregnancy-Induced Hypertension

Nicotine Inhibits Cytokine Production by Placenta Cells via NFκB: Potential Role in Pregnancy-Induced Hypertension

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age

Contact Info

Product

Resources

About